



The European Agency for the Evaluation of Medicinal
Products
Veterinary Medicines and Information Technology Unit

CVMP/VICH/900/99
London, 25 May 2000

**VICH Topic GL4
(Validation: Definition)**

Step 7 Consensus Guideline

**GUIDELINE ON STABILITY TESTING FOR NEW
VETERINARY DOSAGE FORMS**

TRANSMISSION TO CVMP	April 1998
TRANSMISSION TO INTERESTED PARTIES	April 1998
COMMENTS REQUESTED BEFORE	31 August 1998
FINAL APPROVAL BY CVMP	June 1999
DATE FOR COMING INTO OPERATION BY	May 2000

7 Westferry Circus, Canary Wharf, London E14 4HB, UK
Tel (44-20) 74 18 84 00 Fax (44-20) 74 18 84 47

E-mail: mail@emea.eudra.org <http://www.eudra.org/emea.html>

EMEA 2000 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged

STABILITY TESTING FOR NEW VETERINARY DOSAGE FORMS

Recommended for Implementation
at Step 7 of the VICH Process
on 20 May 1999
by the VICH Steering Committee

THIS GUIDELINE HAS BEEN DEVELOPED BY THE APPROPRIATE VICH EXPERT WORKING GROUP ON THE BASIS OF THE ICH GUIDELINES ON THE SAME SUBJECT AND HAS BEEN SUBJECT TO CONSULTATION BY THE PARTIES, IN ACCORDANCE WITH THE VICH PROCESS. AT STEP 7 OF THE PROCESS THE FINAL DRAFT IS RECOMMENDED FOR ADOPTION TO THE REGULATORY BODIES OF THE EUROPEAN UNION, JAPAN AND USA.

STABILITY TESTING FOR NEW VETERINARY DOSAGE FORMS

Recommended for Implementation at Step 7 of the VICH Process
on 20 May 1999 by the VICH Steering Committee

GENERAL

This document is an annex to the VICH parent stability guideline, Stability Testing of New Drug Substances and Products in the Veterinary Field (VICH GL3) and addresses the recommendations on what should be submitted regarding stability of new dosage forms by the owner of the original application, after the original submission for new drug substances and products.

NEW DOSAGE FORMS

A new dosage form is defined as a drug product which is a different pharmaceutical product type, but contains the same active substance as included in the existing drug product approved by the pertinent regulatory authority.

Such pharmaceutical product types include products of different administration route (e.g., oral to parenteral), new specific functionality/delivery systems (e.g., immediate release tablet to modified release tablet) and different dosage forms of the same administration route (e.g. capsule to tablet, solution to suspension).

Stability protocols for new dosage forms should follow the guidance in the parent stability guideline in principle. However, a reduced stability database at submission time may be acceptable in certain justified cases.